Electrocore ( (ECOR) ) has released its Q2 earnings. Here is a breakdown of the information Electrocore presented to its investors.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Electrocore, Inc. is a commercial-stage bioelectronic technology company specializing in non-invasive neuromodulation therapies for chronic pain and wellness, leveraging innovative bioelectronic technologies.
In its latest earnings report, Electrocore announced a significant increase in revenue for the second quarter of 2025, with net sales reaching $7.4 million, marking a 20% growth compared to the same period in 2024. The company also highlighted a successful acquisition of NeuroMetrix, Inc., which was integrated ahead of schedule.
Key financial metrics revealed a year-to-date revenue of $14.1 million, a 22% increase from the first half of 2024. The company’s gross profit for the quarter was $6.4 million, with an 87% gross margin. Despite the revenue growth, Electrocore reported a GAAP net loss of $3.7 million, primarily due to increased selling, general, and administrative expenses.
Electrocore’s strategic focus on the Veterans Administration market and the expansion of its product lines, including nonprescription wellness products like Truvaga and TAC-STIM, contributed to the revenue growth. However, the company also experienced a rise in operating expenses, partly due to increased marketing efforts and professional fees related to the NURO acquisition.
Looking ahead, Electrocore expects to achieve total revenue of approximately $30 million for the full year of 2025, with plans to continue investing in sales and marketing to support its commercial efforts across major U.S. channels.